Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome

European Journal of Endocrinology
Bente HalvorsenPål Aukrust

Abstract

Thiazolidinediones (TZDs) reduce insulin resistance, but also have pleiotropic properties including effects on inflammation. The balance between protective and proatherogenic effects may differ in various patient populations. We studied the effect of rosiglitazone on inflammatory markers in patients with metabolic syndrome (MetSyn). In a cross-over randomized controlled trial, 23 subjects with MetSyn were assigned to treatment with rosiglitazone that was uptitrated from 4 mg/day for 6 weeks followed by 8 mg/day for 6 weeks or matching placebo for 12 weeks, and then to the opposite treatment for 12 weeks. Plasma levels of inflammatory and metabolic markers were measured during follow-up. Our main findings were i) compared to placebo, rosiglitazone significantly decreased the plasma levels of the naturally occurring interleukin (IL)1 inhibitor, IL1 receptor antagonist (IL1Ra; P=0.001), potentially reflecting inflammatory effects on the IL1 system; ii) parallel to this, rosiglitazone decreased plasma levels of IL10 (P=0.029) further suggesting inflammatory effects; iii) rosiglitazone decreased uric acid levels (P=0.001), and monocyte chemoattractant protein-1 (P=0.05) and C-reactive protein (P=0.06) tended to be lower after rosigl...Continue Reading

Citations

Apr 30, 2011·Journal of Inflammation·Joseph ShalhoubClaudia Monaco
Jun 28, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ajaykumar N SharmaJair C Soares
Jan 19, 2018·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Chii-Min HwuBang-Gee Hsu
Jul 21, 2010·Current Opinion in Cardiology·Rajesh Tota-MaharajMichael J Blaha
Sep 22, 2011·Alimentary Pharmacology & Therapeutics·T DogruS Bagci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here